<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119972</url>
  </required_header>
  <id_info>
    <org_study_id>ZSP1603-20-02</org_study_id>
    <nct_id>NCT05119972</nct_id>
  </id_info>
  <brief_title>Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）</brief_title>
  <official_title>A Multi-center, Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, PK and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Raynovent Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Raynovent Biotech Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was divided into two parts. The first part was a dose escalation study: a open&#xD;
      label dose escalation design was used to evaluate the safety, tolerance and pharmacokinetic&#xD;
      characteristics of ZSP1603 in IPF patients. The second part was a randomized double-blind&#xD;
      placebo-controlled design was used to preliminatively investigate the efficacy and safety of&#xD;
      ZSP1603 in the treatment of IPF at the target dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2021</start_date>
  <completion_date type="Anticipated">October 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 21, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The trial has two parts, a part 1 and a part 2, in part 1 will be unblinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>TEAEs will be summarized displaying the number of TEAEs along with the number and percentage of participants with at least one TEAE according to: Number of AEs, Severity and relation to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of ZSP1603</measure>
    <time_frame>up to 15 Days</time_frame>
    <description>Pharmacokinetic analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FVC From Baseline at 12 weeks</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Change of Forced Vital Capacity (FVC) evaluated from baseline until 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FVC%Pred from baseline at 12 weeks</measure>
    <time_frame>up to12 weeks</time_frame>
    <description>Change of predicted Forced Vital Capacity (FVC) (% Predicted) evaluated from baseline until 12 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis (IPF)</condition>
  <arm_group>
    <arm_group_label>part1:ZSP1603 dose1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>part1:ZSP1603 dose2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>part1:ZSP1603 dose3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2: ZSP1603 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1603</intervention_name>
    <description>ZSP1603 administered orally</description>
    <arm_group_label>Part2: ZSP1603 dose</arm_group_label>
    <arm_group_label>part1:ZSP1603 dose1</arm_group_label>
    <arm_group_label>part1:ZSP1603 dose2</arm_group_label>
    <arm_group_label>part1:ZSP1603 dose3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally</description>
    <arm_group_label>Part2: placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IPF diagnosed, according to 2018 American Thoracic Society (ATS), European Respiratory&#xD;
             Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic Association&#xD;
             (ALAT) IPF guideline for diagnosis and management;&#xD;
&#xD;
          -  Dlco (corrected for Hb): 30%-79% predicted of normal;&#xD;
&#xD;
          -  FVC&gt;= 50% predicted of normal;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FEV1/FVC&lt; 0.7;&#xD;
&#xD;
          -  PaO2 in resting state without oxygen inhalation &lt; 50mmHg;&#xD;
&#xD;
          -  Subjects who were likely to be lung transplant recipients or expected to survive less&#xD;
             than 1 year during the study period as assessed by the investigator;&#xD;
&#xD;
          -  Poorly controlled cardiovascular and cerebrovascular diseases;&#xD;
&#xD;
          -  Patients who had used nidanib, pirfenidone, interferon, n-acetylcysteine,&#xD;
             azathioprine, cyclophosphamide, cyclosporine, prednisone &gt; 15mg/ day (or equivalent&#xD;
             dose of other glucocorticoids) within 4 weeks before enrollment; Those who had used&#xD;
             Chinese herbal medicine or acupuncture treatment within 1 week before enrollment;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huiping Li, Professor</last_name>
    <phone>021-65115006</phone>
    <email>liw2013@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Lung Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiping Li, Professor</last_name>
      <phone>021-65115006</phone>
      <email>liw2013@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

